Related Experiment Videos
Serum angiotensin-converting enzyme in malignant lymphomas, leukaemia and multiple myeloma
Insights
Serum angiotensin-converting enzyme (SACE) levels are depressed in patients with hematologic malignancies, particularly chronic leukemia and multiple myeloma. Low SACE activity may indicate a poor prognosis in non-Hodgkin lymphoma patients.
Area of Science:
- Hematology
- Oncology
- Biochemistry
Background:
- Serum angiotensin-converting enzyme (SACE) is an enzyme involved in various physiological processes.
- Elevated SACE levels are characteristic of granulomatous diseases like sarcoidosis.
- The role of SACE in hematologic malignancies is not well understood.
Purpose of the Study:
- To investigate SACE levels in patients with different hematologic malignancies.
- To explore the correlation between SACE activity and disease characteristics, prognosis, and other clinical factors.
Main Methods:
- SACE levels were measured in patients diagnosed with Hodgkin's disease, non-Hodgkin lymphoma, acute leukemia, chronic leukemia, and multiple myeloma.
- Patient data including disease stage, histopathology, treatment, and prognosis were collected.
- SACE levels were compared between patient groups and with healthy controls.
Main Results:
- SACE levels were significantly lower in all analyzed hematologic malignancy groups compared to healthy controls (19.9 vs 24.4 mu/ml, P < 0.001).
- The most pronounced depression of SACE activity was observed in chronic leukemia and multiple myeloma.
- In non-Hodgkin lymphoma, lower SACE activity was associated with a poorer prognosis.
- No correlation was found between SACE activity and disease stage, activity, histopathology, treatment, or mediastinal involvement in Hodgkin's disease.
Conclusions:
- SACE activity is generally depressed in patients with hematologic malignancies.
- Low SACE levels may serve as a prognostic marker in non-Hodgkin lymphoma.
- The unexplained depression of SACE in these conditions warrants further investigation into its pathophysiological significance.
- SACE analysis could be valuable in differentiating hematologic conditions from granulomatous diseases presenting with similar symptoms.
Abstract:
Serum angiotensin-converting enzyme (SACE) was analysed in 27 patients with Hodgkin's disease, 25 with non-Hodgkin lymphoma, 14 with acute leukaemia, 15 with chronic leukaemia, and 15 with multiple myeloma. SACE was depressed in these patients as a whole, with a mean level of 19.9 mu/ml, compared with 116 healthy controls (mean 24.4 mu/ml, P < 0.001). This depression was greatest in chronic leukaemia and multiple myeloma. In Hodgkin's disease no relationship was found between enzyme activity and stage, activity, histopathology, treatment, mediastinal involvement or prognosis. In non-Hodgkin patients a poor prognosis was generally associated with low SACE activity. The low SACE activity was not related to recent corticosteroid treatment, and the cause and pathophysiological significance is unexplained. Since SACE is high in the granulomatous disorder sarcoidosis (which can mimic malignant lymphnode and blood diseases) SACE analysis can be valuable in evaluating patients with mediastinal lymphadenopathy and those in whom non-caseating epitheliod granulomas are found.